• Explore /
  • Poster
  • / A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).

A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).

Abstract Poster

Authors

null

Elizabeth M. Burton

The University of Texas MD Anderson Cancer Center, Houston, TX

Elizabeth M. Burton , Timothy Woody , Isabella Claudia Glitza , Rodabe Navroze Amaria , Emily Zhi-Yun Keung , Adi Diab , Sapna Pradyuman Patel , Michael K.K. Wong , Cassian Yee , Patrick Hwu , Jennifer Leigh McQuade , Scott Eric Woodman , Michael T. Tetzlaff , Michael A. Davies , Jennifer Ann Wargo , Kunal Rai , Hussein Abdul-Hassan Tawbi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02816021

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9560)

DOI

10.1200/JCO.2019.37.15_suppl.9560

Abstract #

9560

Poster Bd #

131

Abstract Disclosures

Similar Posters

First Author: Emily Keung

First Author: Hussein Abdul-Hassan Tawbi

First Author: Timothy Jay Price

First Author: Brian Gastman